Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction

NCT07488689 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

568

Enrollment

OTHER

Sponsor class

Conditions

Septic Shock

Interventions

DRUG: Dapaglifozin
DRUG: Placebo

Sponsor

University Hospital, Strasbourg, France